Novartis AG Deferred Tax Expense Income
Novartis AG (NVS) reported Deferred Tax Expense Income of -$360.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2026-02-04
| Period end | Deferred Tax Expense Income 12 month | Deferred Tax Expense Income 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$360.00M 20-F · filed 2026-02-04 | |
| 2024-12-31 | -$682.00M 20-F · filed 2026-02-04 | |
| 2023-12-31 | -$1.88B 20-F · filed 2026-02-04 | |
| 2022-12-31 | -$625.00M 20-F · filed 2025-01-31 | -$655.00M 20-F · filed 2023-02-01 |
| 2021-12-31 | -$297.00M 20-F · filed 2024-01-31 | -$309.00M 20-F · filed 2023-02-01 |
| 2020-12-31 | -$293.00M 20-F/A · filed 2023-05-15 | |
| 2018-12-31 | -$582.00M 20-F · filed 2019-01-30 | |
| 2017-12-31 | -$760.00M 20-F · filed 2019-01-30 | |
| 2016-12-31 | -$1.01B 20-F · filed 2019-01-30 |